Pharma — Juli 2023
-
Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline https://www.proinvestor.com/investornyt/1016637/lilly-says-its-alzheimers-drug-significantly-slowed-cognitive-and-functional-decline
-
JP Morgan Maintains Johnson & Johnson (JNJ) Neutral Recommendation https://www.proinvestor.com/investornyt/1019609/jp-morgan-maintains-johnson-amp-johnson-jnj-neutral-recommendation
-
Credit Suisse Maintains Johnson & Johnson (JNJ) Neutral Recommendation https://www.proinvestor.com/investornyt/1019608/credit-suisse-maintains-johnson-amp-johnson-jnj-neutral-recommendation
-
Morgan Stanley Reiterates Johnson & Johnson (JNJ) Equal-Weight Recommendation https://www.proinvestor.com/investornyt/1019610/morgan-stanley-reiterates-johnson-amp-johnson-jnj-equal-weight-recommendation
-
GSK : ViiV's Cabotegravir For HIV Prevention Receives Positive CHMP Opinion From EMA https://www.proinvestor.com/investornyt/1019886/gsk-viivs-cabotegravir-for-hiv-prevention-receives-positive-chmp-opinion-from-ema
-
Sandoz Obtains Positive CHMP Opinion For Multiple Sclerosis Biosimilar Natalizumab https://www.proinvestor.com/investornyt/1019879/sandoz-obtains-positive-chmp-opinion-for-multiple-sclerosis-biosimilar-natalizumab
-
Dagens aktie er Regeneron
Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc. er en amerikansk bioteknologivirksomhed der forsker, udvikler, fabrikerer og klargør medicin til markedet https://proinvestor.com/boards/114238/
-
Roche tynget af svindende efterspørgsel på coronamidler i første halvår
https://www.proinvestor.com/investornyt/1022152/roche-tynget-af-svindende-eftersporgsel-pa-coronamidler-i-forste-halvar -
Japansk Lundbeck-partner leverer over forventning https://www.proinvestor.com/investornyt/1022171/japansk-lundbeck-partner-leverer-over-forventning
-
Sanofi Q2 Profit Rises, Sales Up 3.3% At CER; Raises 2023 Business EPS Guidance https://www.proinvestor.com/investornyt/1023041/sanofi-q2-profit-rises-sales-up-33-at-cer-raises-2023-business-eps-guidance
-
Medicinalselskabet Bristol-Myers Squibb kunne inden børsåbning vise sløje resultater for andet kvartal samt en nedjustering af forventningerne drevet af et skuffende salg af kræftmidlet Revlimid.
Det blev der kvitteret for med et fald til aktien på 3,8 pct. torsdag. -
AstraZe neca Plc (AZN) Q2 2023 Earnings Call Transcript https://www.proinvestor.com/investornyt/1023552/astrazeneca-plc-azn-q2-2023-earnings-call-transcript
-
Piper Sandler Maintains Abbvie (ABBV) Overweight Recommendationhttps://www.proinvestor.com/investornyt/1023913/piper-sandler-maintains-abbvie-abbv-overweight-recommendation
-
Is GSK Stock Worth Buying Right Now? https://www.proinvestor.com/investornyt/1024057/is-gsk-stock-worth-buying-right-now
-
The Top Healthcare Stocks to Buy With $100 https://www.proinvestor.com/investornyt/1024104/the-top-healthcare-stocks-to-buy-with-100
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind